Literature DB >> 8440916

Tumor progression in ocular melanomas.

R Folberg1.   

Abstract

The term ocular melanoma refers to a heterogeneous group of cancers of melanocytic origin. The precursor of most cases of conjunctival melanoma is known to ophthalmologists as primary acquired melanosis. This condition passes through well-defined stages of tumor progression. Although tumor progression is not obligatory, as a conjunctival melanocytic lesion acquires new biologic properties it is more likely to progress further. Although junctional nevi are seldom encountered beyond childhood and primary acquired melanosis usually develops in middle-aged individuals, these two conditions may be histologically indistinguishable. Most junctional nevi eventually show evidence of differentiation, whereas nearly half of the cases of primary acquired melanosis with atypia progress to melanoma. Therefore, it is possible that aging may modulate the capability of certain clonal proliferations to differentiate. Uveal melanocytes normally reside in mesenchyme, so that the traditional histologic criterion for establishing the diagnosis of most melanomas--breach of an epithelial basement membrane--does not apply. Because uveal melanomas are not easily accessible to incisional biopsy (without disruption of vision), only two points in the spectrum of tumor progression are defined clinically: nevus and melanoma. Experimental evidence suggests that a spectrum of atypical melanocytic proliferations separates benign nevi from melanomas capable of generating metastases. Unlike conjunctival melanomas that spread first to regional lymph nodes, choroidal and ciliary body melanomas preferentially spread first to the liver and are examples of organ-specific metastases.

Entities:  

Mesh:

Year:  1993        PMID: 8440916     DOI: 10.1111/1523-1747.ep12470222

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

Review 1.  Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name?

Authors:  M J Bissell
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

2.  The molecular classification of uveal melanocytic lesions: an important discovery in context.

Authors:  Robert Folberg
Journal:  J Mol Diagn       Date:  2010-06-03       Impact factor: 5.568

Review 3.  Conjunctival melanoma in Southwestern Nigeria: a case series and review of literature.

Authors:  Oluyemi Fasina; Olayiwola A Oluwasola
Journal:  Int Ophthalmol       Date:  2017-06-19       Impact factor: 2.031

4.  Whole body PET/CT for initial staging of choroidal melanoma.

Authors:  P T Finger; M Kurli; S Reddy; L B Tena; A C Pavlick
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

Review 5.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

6.  Mapping the Location of Prognostically Significant Microcirculatory Patterns in Ciliary Body and Choroidal Melanomas.

Authors:  Robert Folberg; Margaret Fleck; Mary G Mehaffey; Margaret Meyer; Suzanne E Bentler; Robert F Woolson; Jacob Pe'er
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 7.  Indications for surgical resection of metastatic ocular melanoma. A case report and review of the literature.

Authors:  J D Cunningham; E Cirincione; A Ryan; J Canin-Endres; S Brower
Journal:  Int J Pancreatol       Date:  1998-08

8.  MIB-1 and PC-10 immunostaining for the assessment of proliferative activity in primary acquired melanosis without and with atypia.

Authors:  I Chowers; N Livni; A Solomon; G Zajicek; J Frucht-Pery; R Folberg; J Pe'er
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.